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Abstract
Background: Prompt diagnosis of acute HIV infection (AHI) benefits the individual and provides opportunities for public
health intervention. The aim of this study was to describe most common signs and symptoms of AHI, correlate these with
early disease progression and develop a clinical algorithm to identify acute HIV cases in resource limited setting.
Methods: 245 South African women at high-risk of HIV-1 were assessed for AHI and received monthly HIV-1 antibody and
RNA testing. Signs and symptoms at first HIV-positive visit were compared to HIV-negative visits. Logistic regression
identified clinical predictors of AHI. A model-based score was assigned to each predictor to create a risk score for every
woman.
Results: Twenty-eight women seroconverted after a total of 390 person-years of follow-up with an HIV incidence of 7.2/100
person-years (95%CI 4.5–9.8). Fifty-seven percent reported $1 sign or symptom at the AHI visit. Factors predictive of AHI
included age,25 years (OR= 3.2; 1.4–7.1), rash (OR= 6.1; 2.4–15.4), sore throat (OR= 2.7; 1.0–7.6), weight loss (OR= 4.4; 1.5–
13.4), genital ulcers (OR= 8.0; 1.6–39.5) and vaginal discharge (OR= 5.4; 1.6–18.4). A risk score of 2 correctly predicted AHI in
50.0% of cases. The number of signs and symptoms correlated with higher HIV-1 RNA at diagnosis (r = 0.63; p,0.001).
Conclusions: Accurate recognition of signs and symptoms of AHI is critical for early diagnosis of HIV infection. Our
algorithm may assist in risk-stratifying individuals for AHI, especially in resource-limited settings where there is no routine
testing for AHI. Independent validation of the algorithm on another cohort is needed to assess its utility further. Point-of-
care antigen or viral load technology is required, however, to detect asymptomatic, antibody negative cases enabling early
interventions and prevention of transmission.
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Introduction
The devastating toll of the HIV/AIDS epidemic on sub-
Saharan Africa, with 67% of the estimated 33.3 million world-
wide HIV infections in this region alone, is well recognized [1].
Individuals with acute HIV infection (AHI) have been shown to be
more infectious compared to individuals with chronic infection.
Data from several cohorts provide estimates of HIV transmission
per coital act in sub-Saharan Africa, with dramatically higher
transmission rates during acute and early, compared to latent or
chronic infection [2–4]. One study modeling the impact of
antiretroviral therapy (ART) on the HIV epidemic estimated that
38.4% of ongoing HIV transmissions are attributable to sexual
contact with early HIV index cases [5]. This is presumably due to
several factors including very high plasma and genital tract HIV
viral load [6–9]. Early identification of individuals in the acute/
early stage of infection would not only enable prompt intervention
to prevent transmission to negative partners, but may also allow
for earlier initiation of treatment. Data on the clinical benefits of
ART in patients with acute HIV are conflicting [10–12].
Theoretical benefits of this intervention include potentially pre-
serving immune function, reducing the pool of latently infected
CD4 cells, thereby altering the virologic set point and delaying
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disease progression. These have to be weighed against side effects
and patient readiness to start antiretrovirals [3,13–17].
Making the diagnosis of acute HIV infection is challenging since
the signs and symptoms of acute retroviral syndrome are non-
specific. Of note, data on clinical characteristics of subtype C
infection, particularly among women, are currently limited
[18,19]. Days to weeks after acquisition, 40–90% of individuals
develop signs and symptoms including a flu-like illness or
mononucleosis-like syndrome [20]. The onset of symptoms
coincides with viral replication and peak viremia [21–23]. During
this window period, only HIV RNA can be detected in plasma
until the appearance of p24 antigen and, subsequently, HIV
antibodies. Laboratory-based fourth generation Ag/Ab combina-
tion assays improve detection of acutely-infected individuals
compared to third generation antibody assays. However, in
resource limited, high prevalence settings, health services rely
predominantly on point-of-care testing (POCT) and, disappoint-
ingly, a recent evaluation found that the antigen component of the
fourth generation DetermineH HIV-1/2 Ag/Ab Combo rapid test
performed poorly in detecting acute infection [24]. Initiating RNA
testing still requires clinician’s high index of suspicion and
availability of resources. Thus, a clinical algorithm which
prioritizes nucleic acid HIV testing would be of benefit, especially
in decentralized health care settings.
The study, conducted by the Centre for the AIDS Programme
of Research in South Africa (CAPRISA), was a prospective cohort
study to examine the pathogenesis of acute HIV subtype C
infection and to describe the immunologic, virologic and clinical
characteristics of acute and early infection [25]. The purpose of
the current analysis was (i) to describe the signs and symptoms of
AHI in order to develop a diagnostic model for identifying cases
with high probability of AHI which would allow interventions like
targeted HIV-1 RNA or p24 antigen testing; (ii) to calculate
sensitivity and specificity of the risk score to predict presence or
absence of AHI; (iii) to correlate clinical signs and symptoms of
AHI with early virologic and clinical progression of HIV.
Methods
Ethics Statement
Ethics approval for the study was obtained from the University
of KwaZulu-Natal and the University of Cape Town. Written
informed consent was obtained from all participants.
Cohort
Between August 2004 and May 2005, a cohort of 245 HIV-
uninfected women at high risk of infection was recruited in
Durban, South Africa [25]. Women were considered high-risk if
they reported having more than three sexual partners in the past 3
months or self-identified as sex workers.
Study Evaluations and Definition of Acute HIV Infection
Demographic and behavioural questionnaires were adminis-
tered at enrollment. Women were evaluated at baseline and
monthly thereafter with standardized interviews using a locally
developed Clinical Evaluation Tool (CET) to screen for signs and
symptoms associated with AHI. Interviews were performed by the
research clinician who either spoke the local language or was
assisted by a nurse who acted as an interpreter. Signs and
symptoms screened for included: fever, fatigue, lethargy, night
sweats, rash, headache, swollen lymph glands, sore throat,
myalgia, any swollen joints, morning stiffness (joints), nausea,
vomiting, diarrhoea, mucocutaneous ulceration, gingivitis, loss of
appetite, reported weight loss, confusion, photophobia, neck
stiffness, retro-orbital pain and vaginal discharge. Women also
underwent a physical examination to determine the presence or
absence of fever (.38uC), measured weight loss, evidence of rash,
lymphadenopathy, pharyngitis, thrush, mucocutaneous ulceration,
conjunctivitis, hepatomegaly and splenomegaly. Whilst sexually
transmitted infections (STIs) were managed syndromically, six
monthly laboratory screening for STIs was performed as well.
The CET was administered before the HIV status was
established. HIV testing algorithm consisted of two rapid HIV-1
antibody tests: the Determine HIV-1 test (Abbott Diagnostics,
Johannesburg, South Africa) and the Capillus HIV-1/HIV-2 test
(Trinity Biotech, USA). Discordant rapid antibody results were
confirmed by HIV enzyme immunoassay (EIA) (BEP 2000; Dade
Behring, Marburg, Germany). A pooled plasma HIV-1 RNA
(AMPLISCREENTM HIV-1 Tests, v1.5– Roche Diagnostics) was
performed at enrollment and each visit subsequently, irrespective
of antibody result. A primary pool containing 24 samples was used
and if positive disaggregated into smaller secondary pools.
Diagnosis of AHI was made if a woman had detectable plasma
HIV RNA level (using ,400 copies/mL lower limit of detection
assay) and/or a positive HIV antibody test following a previously
documented negative test. Women presenting for unscheduled
visits also completed a CET and were tested for HIV following the
same algorithm. Participants underwent risk reduction counseling
and were provided with male and female condoms at every visit.
Data Analysis
Signs and symptoms reported on the CET at all HIV-negative
visits and the AHI visit were used in the analysis. Prevalence of
signs and symptoms at both the AHI and non-AHI visits was
assessed. Weight before and after seroconversion was compared
using a Wilcoxon signed rank test. A Pearson’s correlation
coefficient was calculated to assess the strength of the linear
relationship between the number of signs and symptoms and viral
load, as well as CD4 count, measured at seroconversion, 6 and 12
months post infection. Signs/symptoms at the AHI visit were
compared to those captured on the CET at HIV-negative visits
from both seroconverters and those who remained HIV negative.
To determine which signs/symptoms were associated with AHI,
symptoms in women who seroconverted were compared with
symptoms in women who remained HIV negative. Odds ratios
(OR) for each of the signs/symptoms were calculated using
a generalized estimating equation model, using a binomial
distribution, accounting for multiple visits for the same participant.
Two adjusted models were fitted to assess clinical factors predictive
of AHI. Variables which were associated with AHI at p,0.15 in
each of the models were then included in the final model, which
was used to develop a model-based score to predict AHI. In
addition to applying a risk score model to predict AHI, the
absolute number of signs/symptoms was also assessed to de-
termine association with AHI. Sensitivity, specificity and positive
likelihood ratios (with 95% confidence intervals) for detecting AHI
were calculated for different numbers of signs and symptoms. This
was also repeated excluding POCT negative, RNA positive
participants reflecting current clinical practice in South Africa
where RNA testing is not part of the algorithm for HIV diagnosis.
All data analysis was performed using SAS version 9.2 (SAS
Institute Inc., Cary).
Results
Demographic Characteristics of the Cohort
Between August 2004 and May 2005, 775 high risk women
were screened and 245 HIV uninfected women were enrolled
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and followed monthly for two years. The demographic and
behavioural characteristics of the 245 women have been
described in detail elsewhere [25] and are summarized in
Table 1. Briefly, the median age of the participants was 36
(interquartile range (IQR): 24–42) years, 41.2% had at least 11
years of education, 58.8% reported using a condom at last sexual
encounter, 13.9% and 35.0% indicated that they were never able
to insist on condom use with casual and steady partners,
respectively [26]. Most women (85.4%) reported having 2–5
casual partners in the 3 months prior to enrollment and 78.8%
were self-identified commercial sex workers. Of note, the
prevalence of HIV among women screening for enrollment into
the HIV negative cohort was 59.6% [25].
Signs and Symptoms in Acute HIV Infection
The 245 HIV negative women had 4845 HIV negative visits,
scheduled monthly, with a missed visit rate of 3.9%. The median
time between visits was 28 days (IQR 28 - 34 days). Twenty-eight
women seroconverted after a total of 390 person-years of follow-up
with an HIV incidence of 7.2/100 person-years (95%CI: 4.5–9.8).
The frequency of signs/symptoms reported at AHI visit was
higher than that reported at the HIV-negative visits (Table 2). The
most prevalent signs/symptoms reported at AHI visit were loss of
appetite (28.6% vs. 2.1% in HIV uninfected, p,0.001), headache
(25.0% vs. 5.7%, p,0.001), rash (25.0% vs. 2.9%, p,0.001), sore
throat (21.4% vs. 2.1%, p,0.001), fever (17.9% vs. 2.9%,
p,0.001), arthralgia (17.9% vs. 2.9%, p,0.001), and reported
weight loss (21.4% vs. 1.3%, p,0.001). Of note, of the 28 acute
infections, 60.7% (n= 17) had confirmed (measured) weight loss in
the preceding two weeks, with a median reduction of 2.0 kg (IQR
1.3–2.6 kg). The median weight loss during seroconversion for all
women with acute infection was 1.3 kg (IQR 0.0–2.2 kg;
p = 0.025).
Fifty-seven percent of participants with AHI reported at least
one sign or symptom and the specificity and likelihood ratios
increased with an increasing number of reported symptoms
(Table 3). Participants with one to three signs/symptoms were
more likely to have AHI compared to women with no signs/
symptoms (OR=3.9; 95% CI: 1.6–9.2; p = 0.002); and presence
of $4 signs/symptoms was strongly associated with AHI
(OR=17.3; 95% CI: 6.7–44.7; p,0.001). When excluding all
POCT Ab negative, RNA positive AHI cases, the prevalence of
signs/symptoms increased to 76.5% and the association with AHI
was even stronger (1–3 symptoms: OR=10.3; 95% CI: 3.1–34.5,
$4 symptoms: OR=36.9. 95% CI: 9.8–140). When comparing
AHI and non-AHI visits among women who seroconverted, loss of
appetite, fatigue, headache, rash and sore throat remained the
most commonly reported symptoms.
Table 1. Baseline demographic and behavioural characteristics of South African women at high risk of HIV acquisition stratified by
HIV status [25].
Characteristic All % (N) (N=245)
HIV negative % (N)
(N=217)
AHI# cases % (N)
(N=28)
Age in years
$25 73.5% (180) 75.6% (164) 57.1% (16)
,25 26.5% (65) 24.4% (53) 42.9% (12)
Relationship status
No partner (single, widowed, divorced) 7.4% (18/244) 7.9% (17/216) 3.6% (1)
One partner (stable or married) 35.7% (87/244) 37.5% (81/216) 21.4% (6)
Many partners 57.0% (139/244) 54.6% (118/216) 75.0% (21)
Number of casual partners in the last 3 months (baseline)
0–1 5.0% (12/240) 4.7% (10/212) 7.1% (2)
2–5 85.4% (205/240) 85.9% (182/212) 82.1% (23)
.5 9.6% (23/240) 9.4% (20/212) 10.7% (3)
Proportion of commercial sex workers 78.8% (193) 79.7% (173) 71.4% (20)
Highest level of school completed
Grade ,8 24.5% (60) 26.3% (57) 10.7% (3)
Grade 8–10 34.3% (84) 32.3% (70) 50.0% (14)
Grade 11–12 41.2% (101) 41.5% (90) 39.3% (11)
Mean years sexually active (SD) 17.2 (10.38) 17.7 (10.35) 13.5 (10.08)
Age at sexual debut
,16 28.2% (69) 26.7% (58) 39.3% (11)
$16 71.8% (176) 73.3% (159) 60.7% (17)
Partner type at last sexual act (baseline)
Steady Partner 75.9% (186) 77.9% (169) 60.7% (17)
Casual Partner 24.1% (59) 22.1% (48) 39.3% (11)
Proportion with condom use at last sex act 58.8% (144) 58.1% (126) 64.3% (18)
#Acute HIV Infection.
doi:10.1371/journal.pone.0062928.t001
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Factors Predictive of Acute HIV Infection
In an adjusted model, six predictors of AHI were identified: age
,25 years (OR=3.2, 95% CI: 1.4–7.1), rash (OR 6.1, 95% CI:
2.4–15.4), sore throat (OR 2.7, 95% CI: 1.0–7.6), loss of appetite
(OR 4.7, 95% CI: 1.4–15.6), weight loss (OR 4.4, 95% CI: 1.5–
13.4), vaginal discharge (OR: 5.4, 95% CI: 1.6–18.4) and genital
ulcer (OR 8.0, 95% CI: 1.6–39.5) (Table 4). In this cohort,
behavioural factors, including number of partners, condom use,
whether the partner was casual or steady, and educational level
were not associated with AHI in the final model (data not shown).
Signs and Symptoms According to HIV Diagnostic Test
All participants had two POCTs and a viral load RNA performed
at eachvisit. Positive resultswere followedupwitha laboratory-based
third generation ELISA test.Of the 28womenwithAHI, 17 (60.7%)
had positive POCTs including one participant with discordant
POCTs,whileallwereHIVpositiveonRNAtesting (Table5).Three-
quarters of women (13/17; 76.5%) with positive or discordant
POCTs were symptomatic compared to only one quarter with two
negative POCTs at AHI (3/11; 27.3%, p= 0.019) who would have
been identified with our clinical algorithm. However, it is important
to note that, 8/28 women (28.6%) were POCT negative and
experienced no signs or symptoms at the AHI visit and would
therefore not have been identified by POCT testing or any clinical
evaluation of AHI symptoms.
Risk-score Model Predicting Acute HIV Infection
The variables significantly associated with AHI in the adjusted
analysis were used to construct a predictor risk score for AHI using
the regression coefficients from the final adjusted model. The
signs/symptoms in the model were weighted by the regression
coefficients, rounded off to the nearest integer. Hence, the risk
score algorithm was calculated as follows:
Risk Score~2 if rashz1 if sore throatz2 if loss of appetite
z1 if weight lossz2 if vaginal discharge
z2 if genital ulcerz1 if agev25 years
Table 2. Signs and symptoms associated with acute HIV infection.
Signs or symptoms
Total cohort HIV negative
visits
N (%) (N=4845)




(95% CI) p-value Sensitivity (%) Specificity (%)
Headache 277 (5.7) 7 (25.0) 5.5 (2.3–13.0) ,0.001 25.0 94.3
Fever 140 (2.9) 5 (17.9) 7.3 (2.7–19.5) ,0.001 17.9 97.1
Sore throat 100 (2.1) 6 (21.4) 12.9 (5.1–32.6) ,0.001 21.4 97.9
Night sweats 119 (2.5) 3 (10.7) 4.8 (1.4–16.0) 0.012 10.7 97.5
Fatigue 133 (2.7) 7 (25.0) 11.8 (4.9–28.3) ,0.001 25.0 97.3
Swollen glands 280 (5.8) 3 (10.7) 2.0 (0.6–6.5) 0.275 10.7 94.2
Rash 138 (2.8) 7 (25.0) 11.4 (4.8–27.2) ,0.001 25.0 97.2
Loss of appetite 103 (2.1) 8 (28.6) 18.4 (7.9–42.8) ,0.001 28.6 97.9
Weight loss 63 (1.3) 6 (21.4) 20.7 (8.1–52.8) ,0.001 21.4 98.7
Nausea 80 (1.7) 5 (17.9) 12.9 (4.8–34.9) ,0.001 17.9 98.3
Diarrhoea 102 (2.1) 4 (14.3) 7.8 (2.6–22.7) ,0.001 14.3 97.9
Arthralgia 139 (2.9) 5 (17.9) 7.4 (2.8–19.6) ,0.001 17.9 97.1
Myalgia 47 (1.0) 3 (10.7) 12.3 (3.6–42.0) ,0.001 10.7 99.0
Lethargy 49 (1.0) 3 (10.7) 11.7 (3.4–40.2) ,0.001 10.7 99.0
Oral ulcers 48 (1.0) 2 (7.1) 7.7 (1.8–33.3) 0.006 7.1 99.0
Genital ulcers 8 (0.2) 2 (7.1) 46.5 (9.4–229.6) ,0.001 7.1 99.8
Vaginal discharge 91 (1.9) 3 (10.7) 6.3 (1.9–21.1) 0.003 10.7 98.1
*Odds Ratio adjusted for repeated measures.
Note: Signs and symptoms reported with ,5% frequency in the AHI cases or p.0.15 were omitted. These included splenomegaly, anal ulcers, swollen joints, gingivitis,
observed fever, aseptic meningitis, peripheral neuropathy, conjunctivitis, hepatomegaly, photophobia, parasthaesia, retro-orbital headache and neck stiffness.
doi:10.1371/journal.pone.0062928.t002
Table 3. Sensitivity and Specificity for different number of
signs and symptoms.
Number of
symptoms Sensitivity (%) Specificity (%) +LR (95% CI)
All AHI cases included (N=28)
$1 57.1% 81.5% 3.09 (2.23–4.28)
$2 42.9% 91.4% 4.98 (3.22–7.71)
$3 32.1% 95.3% 6.86 (3.95–11.93)
$4 25.0% 97.3% 9.11 (4.69–17.68)
$5 25.0% 98.1% 13.31 (6.79–26.09)
Excluding POCT* negative, RNA positive cases (N=17)
$1 76.5% 81.5% 4.13 (3.15–5.42)
$2 58.8% 91.4% 6.82 (4.54–10.27)
$3 41.2% 95.3% 8.76 (4.89–15.69)
$4 29.4% 97.2% 10.65 (5.00–22.68)
$5 29.4% 98.1% 15.68 (7.30–33.69)
*POCT: point of care test.
doi:10.1371/journal.pone.0062928.t003
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A risk score was calculated for each visit. The sensitivity and
specificity of different cut-off scores were determined by compar-
ing the risk score with the HIV status (HIV-1 RNA and/or
antibody positive) of the participant at every visit. Simply RNA
PCR testing every person with at least one symptom would yield
a sensitivity of 57.1%. A risk score of at least 1 occurred at 28.0%
of participant visits. Having a score of at least 1, that is, presenting
with any of the risk score symptoms or being under 25 years of
age, would identify 67.9% cases of AHI and positive predictive
value (PPV) of the test would be low at 1.4%. Using this scoring
system, a score of 2 could identify 50.0% of AHI cases by testing
only 7.3% of participants, with a PPV of 3.9%. At a cut-off of 3,
only 3.0% of participants would be tested to identify 39.3% of all
AHI, with a PPV of 7.5%.
Correlation of Number of Signs and Symptoms and
Markers of HIV Disease Progression
There was a significant positive correlation between the number
of signs/symptoms and the HIV-1 plasma viral load at the AHI
visit (correlation coefficient of 0.63, p =,0.001) with participants
who had a high viral load at seroconversion having a greater
number of signs/symptoms. However, this trend did not persist,
and no correlation was observed between the initial number of
signs/symptoms and HIV-1 plasma viral loads at 6 or 12 months.
There was no statistically significant correlation between the
number of signs/symptoms and CD4 count at seroconversion
(correlation coefficient of 0.16, p = 0.41). There was also no
significant difference in the duration of signs/symptoms and self-
reported severity of diarrhoea, skin rash, lethargy and pharyngitis
(mild to severe) between women with AHI and HIV-negative
women (data not shown).
Discussion
The period of acute HIV infection contributes to a considerable
proportion of transmission events and, therefore, identifying those
who are acutely infected is of paramount importance in curbing
the epidemic [20]. Accurate diagnosis of acute HIV infection
includes use of molecular techniques like HIV RNA PCR
detection which may either be expensive or not readily available
in some settings.
In this prospective cohort study of 245 high-risk women we
identify clinical signs and symptoms predictive of acute subtype C
infection. We present a screening algorithm which can be used to
enhance detection of acute HIV infection in a resource-limited
setting. Importantly, we report that younger age, rash, sore throat,
loss of appetite, weight loss and vaginal discharge or genital ulcers
were associated with AHI. A similar constellation of symptoms has
been reported in other studies [27–32], although in our cohort
none of the signs or symptoms had prevalence above 28.6%. In
fact, fever, commonly reported in other studies, was found in only
17.9% of our participants [27–32]. Most available data, however,
pertains to predominantly male cohorts with subtype B infection.
Data in the sub-Saharan African context is more limited
[18,19,33], particularly among women with subtype C infection.










$25 1.0 1.0 1.0
,25 2.77 (1.30–5.86) 2.60 (1.23–5.50) 3.15 (1.41–7.07)
Symptoms and Signs
Headache 5.50 (2.32–13.04) – –
Fever 7.31 (2.74–19.50) – –
Sore Throat 12.94 (5.14–32.61) 3.16 (1.01–9.83) 2.73 (0.99–7.56)
Night Sweats 4.77 (1.42–16.00) – –
Fatigue 11.81 (4.93–28.26) – –
Swollen Glands 1.96 (0.59–6.52) – –
Rash 11.37 (4.75–27.19) 5.42 (2.10–13.99) 6.07 (2.39–15.43)
Loss of Appetite 18.42 (7.93–42.78) 4.91 (1.40–17.29) 4.72 (1.42–15.63)
Weight Loss 20.70 (8.12–52.80) 3.50 (1.17–10.41) 4.43 (1.46–13.43)
Nausea 12.95 (4.80–34.91) – –
Diarrhoea 7.75 (2.64–22.74) – –
Athralgia 7.36 (2.76–19.64) – –
Myalgia 12.25 (3.58–41.98) – –
Lethargy 11.74 (3.43–40.19) – –
Oral Ulcers 7.69 (1.77–33.30) – –
Genital Ulcers 46.51 (9.42–229.60) 8.11 (1.97–33.49) 7.95 (1.60–39.49)
Vaginal Discharge 6.27 (1.86–21.13) 6.19 (1.73–22.15) 5.38 (1.57–18.40)
*Model for behavioural and demographic factors adjusted for age in years, relationship status, education and age at sexual debut (data not shown), while model for
symptoms and signs adjusted for sore throat, rash, loss of appetite, weight loss, genital ulcers and vaginal discharge.
**Risk score model adjusting for age, sore throat, rash, loss of appetite, weight loss, genital ulcers and vaginal discharge.
doi:10.1371/journal.pone.0062928.t004
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Available literature on acute infection reports higher prevalence of
symptoms than what was noted in our cohort. For example, in
a prospective cohort of female sex workers in Kenya, 81% of
women had at least one symptom, in comparison to only 57.1% in
our cohort [18]. More recently, in a cross-sectional cohort of
predominantly male adults presenting with fever in Mozambique,
among those identified with acute infection, all had reported sore
throat and 67% complained of a mononucleosis-like syndrome.
The limitation of this particular study, however, was a small
number of individuals with acute HIV infection and that the
administration of the questionnaire a week after the diagnosis visit
may have influenced the findings [34].
Our AHI cohort included individuals who were diagnosed by
RNA testing alone potentially before a possible seroconversion
illness could have manifested itself. Excluding these cases, the
number of women who reported signs/symptoms was 76.5%
similar to what has been previously reported [18,19]. Other
contributing reasons for the observed difference may have been
cultural or gender-specific characteristics in reporting signs/
symptoms, or differences in how HIV subtypes manifest disease
[35]. In addition, the fact that our participants were not being
evaluated in an STI clinic or referred for a particular complaint,
meant that they were probably less likely to report signs/
symptoms. It is therefore possible that if the clinical algorithm
was applied to a primary health care facility or STI clinic, the
sensitivity and specificity of the algorithm would improve, as well
as its utility as part of an HIV screening initiative in these settings.
This study demonstrates that it is possible to create a model
predictive of AHI in this population. RNA-PCR testing everyone
with a risk cut-off of $1 (28.0% of participant visits), would allow
for the identification of 67.9% of acutely-infected individuals. In
contexts of limited resources, the cut-off score could be increased,
thus reducing the number of tests done in order to identify acute
infection. In our cohort, testing only women with a risk score of
$2 would result in RNA-PCR testing of only 7.3% of participant
visits, and half (50.0%) of all acute infections would be identified.
The costs of these additional tests could be offset by the benefit of
being able to intervene early in acutely-infected individuals, to
initiate care and help prevent HIV transmission during this high-
risk period.
Our algorithm did not yield as high a predictive value or
sensitivity as the algorithm created from a cross-sectional
assessment of individuals presenting at an STI clinic in Malawi.
Powers et al, who included discordant POCT results in their
model, were able to identify 95% of AHI cases by performing
RNA or p24 testing in 40% of their population [19]. Apart from
a difference in testing methodologies between the two studies, it is
possible that the models were affected by differences in the
population with higher overall prevalence of signs/symptoms such
as genital ulcer disease in individuals presenting for diagnosis and
treatment at an STI clinic in the Malawi study.
Many demographic factors such as number of sexual partners,
age at sexual debut, education level and condom use were not
significantly associated with AHI in our cohort. A possible
explanation is that behavioural risk assessment was performed
only at enrollment and thus, because of ongoing risk reduction
counseling, it is possible that women modified their risk behaviour
over the course of the study resulting in a decrease of HIV
incidence over time [25]. Only age ,25 years was strongly
predictive of acute HIV infection (OR 3.2). This finding reflects
what has been reported in other studies that indicate a higher
incidence of HIV in younger women [36].
Availability of longitudinal follow-up data from the immediate
post-seroconversion period, allowed us to demonstrate a correla-
tion between the number of signs/symptoms and early HIV RNA
levels. While in our study this association did not persist beyond
the early HIV infection period, previous studies found an
association between the number, severity and duration of
symptoms and higher viral load set-points in patients infected
with subtype B virus [37–39]. For example, one cohort study with
over 600 individuals found that HIV RNA levels remained
persistently higher in symptomatic compared to asymptomatic
patients highlighting the need to identify those individuals and
ensure access to care [40]. Data from sub-Saharan Africa is limited
but our findings differ from what has been reported in a cohort of
women in Kenya where higher set-point viral load and more
severe illness at acute HIV infection predicted faster disease
progression [41,42].
Our study demonstrates that a considerable proportion of
individuals (28.6%) neither test positive on conventional point-of-
care testing nor report any symptoms when presenting to testing
facilities with acute HIV infection. This population provides a true
challenge for the scientific community to develop reliable fourth
generation Ag/Ab combination POCTs or low-cost point-of-care
viral load technology. Although the DetermineH HIV-1/2 Ag/Ab
Combo rapid test performed poorly in detecting acute infection in
a recent trial [24] we hope that this is not the end of POCT Ag
technology. Furthermore, several POCT viral load assays are
currently being evaluated including the SAMBA (simple amplifi-
cation based assay; Diagnostics Development Unit University of
Cambridge) a semi quantitative test for using isothermal ampli-
fication and visual detection by dipstick, the Liat TM Analyser,
manufactured by IQuum (Marlborough, MA), is a real-time,
battery operated, small, portable PCR kit providing quantitative
results and the Alere NAT system (Alere Technologies, Stirling,
UK). The hope would be that the implementation of this
technology, primarily developed in order to monitor HIV positive
patients on ART, will also allow health care providers in less
developed settings to test for AHI.
The strengths of our study rest in the fact that this is
a longitudinal cohort composed of women with subtype C
infection which was conducted in a non-STI clinic setting and
therefore may be more representative of the general population.
The cohort design included clinical assessment at every visit which
allowed comparison of signs/symptoms pre-seroconversion to AHI
visit. Given the poor specificity of signs/symptoms and concurrent
Table 5. Signs and symptoms according to HIV diagnostic test.
HIV diagnostic testing N (%) of AHI cases (N=28) N (%) with no symptoms N (%) with any symptoms p-value*
POCT antibody positive or discordant 17 (60.7%) 4/17 (23.5%) 13/17 (76.5%) 0.0189
POCT antibody negative 11 (39.3%) 8/11 (72.7%) 3/11 (27.3%) –
*Fisher’s Exact test.
doi:10.1371/journal.pone.0062928.t005
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background of other illnesses, this systematic clinical assessment is
an advantage of this study. In contrast to previous studies, all
participants underwent antibody and RNA PCR testing at every
visit allowing a detailed analysis of the characteristics of these tests
and correlation with symptoms.
Our study highlights the challenges associated with recognizing
and diagnosing acute HIV infection in a cohort of women at high
risk of infection. Although signs/symptoms of AHI are non-
specific and highly variable, it is possible to identify a large
proportion of individuals who have acute or early HIV infection if
there is a high index of suspicion to consider the diagnosis and
initiate appropriate testing. More advanced laboratory diagnostic
tools offer promise of earlier detection of incident infections [21],
but even then clinical judgement guiding prioritization of testing
will remain critical, especially in resource-limited settings. Our risk
score model based on several signs/symptoms most predictive of
AHI may allow identification of women likely to be acutely
infected with HIV and prioritize testing with RNA or newer
generation assays, ultimately reducing cost of AHI diagnosis.
Further independent validation of the model in different settings
and larger sero-incidence cohorts would be important to assess the
utility of the model in practice. In a setting where nucleic acid
testing is not yet readily available, the ability to develop a checklist
of signs/symptoms that would increase clinical suspicion of AHI
would be of benefit for triaging of high-risk women and may lead
to earlier detection of infection.
A recent study by Powers and colleagues concluded that in
order to have a large impact on decreasing HIV prevalence, it is
critical to identify and engage in care individuals in acute and early
stages of HIV infection [5]. Thus, rapid detection of incident
infections is an important component of test-and-treat and other
prevention strategies. Screening for AHI is, however, associated
with substantial costs of using newer generation HIV diagnostics
and adds operational challenges [43]. Until rapid and cheap point-
of-care assays which reliably detect HIV RNA or p24 antigen are
commercially available and deployable in resource-limited set-
tings, detecting AHI will remain a challenge. In the meantime,
a clinically relevant risk algorithm which would decrease the
number of individuals needed to screen with laboratory tests to
detect AHI, is critical. The window of opportunity to intervene is
narrow but the potential to benefit the individual and prevent
onward transmission is considerable.
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